Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction [1]

Internal Medicine Journal

Volumn 35, Issue 1, 2005, Pages 67-68

  Soldatos, G ^a   Sztal Mazer, S ^a   Woolley, I ^a   Stockigt, J ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; BECLOMETASONE; BUDESONIDE PLUS FORMOTEROL; CORTICOTROPIN; CORTISONE ACETATE; CYTOCHROME P450 3A; DIDANOSINE; FLUTICASONE; GLUCOCORTICOID; HYDROCORTISONE; IMMUNOGLOBULIN; INDINAVIR; LAMIVUDINE; PREDNISOLONE; RITONAVIR; SALMETEROL; STAVUDINE; TETRACOSACTIDE; ZIDOVUDINE;

AGED; AMNESIA; ASTHMA; AVASCULAR NECROSIS; CANDIDIASIS; CASE REPORT; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CONCENTRATION LOSS; CORTICOSTEROID INDUCED OSTEOPOROSIS; CUSHINGOID SYNDROME; FATIGUE; FOOT DISEASE; FOOT DROP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LETHARGY; LETTER; LIPODYSTROPHY; MALE; OBESITY; OSTEOPENIA; PRIORITY JOURNAL; SOMNOLENCE;

AGED; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; ASTHMA; CUSHING SYNDROME; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYDROCORTISONE; MALE; RITONAVIR;

EID: 13844273228     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2004.00723.x     Document Type: Letter

References (9)

1. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids. Lessons for the new millennium. Drug Safety 2000; 1: 11-33.
2. Chrousos PC, Harris AG. Hypothalamic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy. Neuroimmunomodulation 1998; 5: 288-308.
3. Wilson A, Blumsohn A, Jung RT, Lipworth BJ. Asthma and Cushing's syndrome. Chest 2000; 117: 593-4.
4. Workman C, Hayes J, Kelly M. Iatrogenic Cushing's disease from ritonavir inhibition of fluticasone metabolism. Australasian Society for HIV Medicine, 13th Annual Conference Abstracts in conjunction with the 6th International Congress on AIDS in Asia and the Pacific (abstract 103); 4-7 October 2001; Melbourne, Australia; 92.
5. Clevenbergh P, Corcostegul M, Gerard D, Hietonimus S, Mondain V, Chichmanian RM et al. Iatrogenic Cushing's syndrome in a HIV-infected patient treated with inhaled corticosteroids (fluticasone proprionate) and low dose ritonavir enhanced PI containing regimen. J Infect 2002; 44: 194-5.
6. Gupta SK, Dube MP. Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy. Clin Infect Dis 2002; 35: E69-71.
7. Rouanet I, Peyrire H, Mayboussin JM, Vincent D. Cushing's syndrome in a patient treated by ritonavir/lopinavir and inhaled fluticasone. HIV Med 2003; 4: 149-50.
8. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159: 941-55.
9. Sagir A, Wettstein M, Oette M, Erhardt A, Haussinger D. Budesonide-induced acute hepatitis in a HIV positive patient with ritonavir as co-medication. AIDS 2002; 16: 1191-2.